[go: up one dir, main page]

WO2024214840A1 - Composition for reduction or treatment of skin disease - Google Patents

Composition for reduction or treatment of skin disease Download PDF

Info

Publication number
WO2024214840A1
WO2024214840A1 PCT/KR2023/004927 KR2023004927W WO2024214840A1 WO 2024214840 A1 WO2024214840 A1 WO 2024214840A1 KR 2023004927 W KR2023004927 W KR 2023004927W WO 2024214840 A1 WO2024214840 A1 WO 2024214840A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin disease
reduction
treatment
composition
pharmaceutical composition
Prior art date
Application number
PCT/KR2023/004927
Other languages
French (fr)
Korean (ko)
Inventor
윤종오
Original Assignee
윤종오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윤종오 filed Critical 윤종오
Priority to PCT/KR2023/004927 priority Critical patent/WO2024214840A1/en
Publication of WO2024214840A1 publication Critical patent/WO2024214840A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition for reduction or treatment of intracellular parasite-induced skin disease. The pharmaceutical composition for reduction or treatment of skin disease, comprising an organosilicon ionic liquid and a cell growth factor as active ingredients, of the present invention acts on skin disease including the atopic syndrome and thus may be usefully employed in various areas such as a medicine or a cosmetic material, etc. for reduction or treatment of intracellular parasite-induced skin disease, including the atopic syndrome, and itching.
PCT/KR2023/004927 2023-04-12 2023-04-12 Composition for reduction or treatment of skin disease WO2024214840A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2023/004927 WO2024214840A1 (en) 2023-04-12 2023-04-12 Composition for reduction or treatment of skin disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2023/004927 WO2024214840A1 (en) 2023-04-12 2023-04-12 Composition for reduction or treatment of skin disease

Publications (1)

Publication Number Publication Date
WO2024214840A1 true WO2024214840A1 (en) 2024-10-17

Family

ID=93059519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/004927 WO2024214840A1 (en) 2023-04-12 2023-04-12 Composition for reduction or treatment of skin disease

Country Status (1)

Country Link
WO (1) WO2024214840A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004238302A (en) * 2003-02-04 2004-08-26 Yukitoshi Kubota Silicone compound-containing alkali ion cosmetic
KR20120115535A (en) * 2010-01-06 2012-10-18 오알에프 리프태크니 에이치에프 Method of use of stabilized plant-derived growth factor in skin care
KR20160072090A (en) * 2014-11-17 2016-06-22 주식회사 바이오코즈글로벌코리아 Cosmetic compostion for improvement of skin condition comprising cell culture medium, epidermal growth factor and bovine serum albumin
KR20200124598A (en) * 2019-04-24 2020-11-03 윤종오 Process for producing silicon ion complexes and complexes organicized with carboxylic acid and products using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004238302A (en) * 2003-02-04 2004-08-26 Yukitoshi Kubota Silicone compound-containing alkali ion cosmetic
KR20120115535A (en) * 2010-01-06 2012-10-18 오알에프 리프태크니 에이치에프 Method of use of stabilized plant-derived growth factor in skin care
KR20160072090A (en) * 2014-11-17 2016-06-22 주식회사 바이오코즈글로벌코리아 Cosmetic compostion for improvement of skin condition comprising cell culture medium, epidermal growth factor and bovine serum albumin
KR20200124598A (en) * 2019-04-24 2020-11-03 윤종오 Process for producing silicon ion complexes and complexes organicized with carboxylic acid and products using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOI SUN YOUNG, LEE YOU JIN, KIM JI MIN, KANG HYUN JI, CHO SANG HYUN, CHANG SUNG EUN: "Epidermal Growth Factor Relieves Inflammatory Signals in Staphylococcus aureus -Treated Human Epidermal Keratinocytes and Atopic Dermatitis-Like Skin Lesions in Nc/Nga Mice", BIOMED RESEARCH INTERNATIONAL, vol. 2018, 1 January 2018 (2018-01-01), pages 1 - 9, XP093225086, ISSN: 2314-6133, DOI: 10.1155/2018/9439182 *
COSMETICS KOREA: "Silicon is good for atopic dermatitis and psoriasis", NAVER BLOG, 16 October 2017 (2017-10-16), pages 1 - 6, XP093225137, Retrieved from the Internet <URL:https://m.blog.naver.com/ysj5070/221118016306> [retrieved on 20241118] *
YOON JONG-OH : "Developer Yoon Jong-oh's development of the world's first "organosilicon ionic liquid" has brought health supplements into the spotlight", MONTHLY JOURNAL FOOD & MEDICINE, 13 December 2020 (2020-12-13), pages 1 - 3, XP093225145, Retrieved from the Internet <URL:http://www.xn--p50bo15av1brtd.com/m/content/view.html?section=9&category=101&no=1476> [retrieved on 20241118] *

Similar Documents

Publication Publication Date Title
Burlando et al. Honey in dermatology and skin care: a review
Sanadi et al. The effect of Vitamin C on melanin pigmentation–A systematic review
Younis et al. Green synthesis of silver nanoparticles by the Cyanobacteria synechocystis sp.: Characterization, antimicrobial and diabetic wound-healing actions
Faergemann Management of seborrheic dermatitis and pityriasis versicolor
Kaur et al. A review on antifungal efficiency of plant extracts entrenched polysaccharide-based nanohydrogels
CN1923165B (en) Method for delivering substances to the skin and compositions used therein
Stipcevic et al. Di-rhamnolipid from Pseudomonas aeruginosa displays differential effects on human keratinocyte and fibroblast cultures
AU2012254214B2 (en) A topical formulation for treatment of hyperkeratotic skin
EP2937101A1 (en) Semi-fluidic composition for lubricating, moisture retaining, disinfecting, sterilizing and method using the same
Gold et al. Hypochlorous acid gel technology—Its impact on postprocedure treatment and scar prevention
Bhatia et al. Evaluation of the wound healing potential of isoquercetin-based cream on scald burn injury in rats
US20190290606A1 (en) Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
MX2023007080A (en) Method for treating fibrosis.
Yingsakmongkol et al. Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial
Wargala et al. Snail mucus as an innovative ingredient used in the cosmetology and medical industry
KR102272901B1 (en) Composition for external application to the skin containing meso-2,3-butanediol as a preservative
Mendes et al. Gellan gum spongy‐like hydrogel‐based dual antibiotic therapy for infected diabetic wounds
WO2024214840A1 (en) Composition for reduction or treatment of skin disease
EA202092077A1 (en) LOCAL COMPOSITIONS CONTAINING STRONZIUM AND METHYLSULPHONYLMETHANE (MSM) AND METHODS OF TREATMENT
CN108852900A (en) A kind of antibacterial facial mask and preparation method thereof containing tridecanoic peptide
RU2636530C2 (en) Pharmaceutical compositions for treatment of wounds and burns
ZA946064B (en) Functional oxygenaceous preparation
KR101874830B1 (en) Antibacterial Cosmetics Composition
EP1996014B1 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain
US10166260B2 (en) Wound care product with egg shell membrane

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23933129

Country of ref document: EP

Kind code of ref document: A1